Health Catalyst beats Q3 rev midpoint; raises FY rev guidance; Adj. EBITDA positive

Health Catalyst, Inc.

2023-Q3 EPS reported -$1.57 revenue$220,854,000

Total revenue $73.8M (+8% YoY); tech revenue $46.0M (+4%), pro services $27.8M (+14%).
Net loss $22.0M vs $45.7M loss YoY (improved 52%); loss from ops $24.6M vs $45.7M.
Adjusted EBITDA $2.0M vs ($4.6M) loss a year ago; Q3 beat midpoint on both rev and EBITDA.
Raised FY2023 revenue guidance range; reiterated FY2023 Adjusted EBITDA guidance.
Full Q3 results and conference call rescheduled to November 2, 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.87

Health Catalyst, Inc. reported the quarter ended September 30, 2023 results: revenue $73.8 million. Guidance raised.

Period: the quarter ended September 30, 2023
Revenue: $73.8 million
Guidance: raised
Result: preliminary results

Exact text from the filing

timing. See below for quarterly conference call details. “For the third quarter of 2023, I am pleased by our strong preliminary financial results, including total revenue of $73.8 million and Adjusted EBITDA of $2.0 million, with these results beating the mid-point of our quarterly guidance on each metric. Additionally, we are grateful to be in a position to raise

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

Health Catalyst, Inc. filing history →

Source: SEC EDGAR

accession 0001636422-23-000124

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.